IRVING, Texas, Feb. 16, 2010 (GLOBE NEWSWIRE) -- Caris Life Sciences (Caris®) -- a leading provider of integrated anatomic pathology and oncology testing services, including molecular profiling and hematopathology -- today announced the launch of The Caris RegistrySM, a biomarker-driven repository to help predict clinical benefit and patients' responses to cancer therapy including chemotherapy, immunotherapy and biological therapy.
